Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 3
1982 1
1985 2
1994 1
1996 1
2005 1
2007 1
2008 2
2009 3
2010 1
2011 4
2012 1
2013 5
2014 3
2015 3
2016 1
2017 11
2018 9
2019 11
2020 12
2021 13
2022 10
2023 23
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Hansen DK, et al. Among authors: khouri j. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623248 Free PMC article.
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: khouri j. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Daratumumab monotherapy for relapsed POEMS syndrome.
Dima D, Valent J, Khouri J. Dima D, et al. Among authors: khouri j. Am J Hematol. 2023 Nov;98(11):E291-E294. doi: 10.1002/ajh.27050. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548551 No abstract available.
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.
Rafae A, Ehsan H, Wahab A, Khan SI, Khan I, Ashraf S, Ali S, Khalid F, Neupane K, Valent J, Khouri J, Samaras C, Mazzoni S, Anwer F. Rafae A, et al. Among authors: khouri j. Crit Rev Oncol Hematol. 2022 Aug;176:103744. doi: 10.1016/j.critrevonc.2022.103744. Epub 2022 Jun 15. Crit Rev Oncol Hematol. 2022. PMID: 35717005 Review.
Multiple Myeloma Therapy: Emerging Trends and Challenges.
Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Dima D, et al. Among authors: khouri j. Cancers (Basel). 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082. Cancers (Basel). 2022. PMID: 36077618 Free PMC article. Review.
Ethical Challenges in CAR-T slot allocation.
Faiman B, Khouri J, Williams LS, Anwer F. Faiman B, et al. Among authors: khouri j. Transplant Cell Ther. 2023 Apr;29(4):215-216. doi: 10.1016/j.jtct.2023.03.003. Transplant Cell Ther. 2023. PMID: 36966011 Free article. No abstract available.
120 results